Optimizing the use of cyclosporine in renal transplantation

Sketris, Ingrid; Yatscoff, Randall W.; Keown, Paul; Canafax, Daniel M.; First, M. Roy; Holt, David W.; Schroeder, Timothy; Wright, Matthew

doi:10.1016/0009-9120(95)91341-y

Cited by 48 publications

(24 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cyclosporin A (CsA) is a potent immunosuppressant, which has been widely used to prevent organ rejection (Sketris et al 1995). It is well accepted that CsA can inhibit activation of T cells through suppressing the Ca 2C /calcineurin/calmodulin/NFAT signaling pathway that is important to the transcriptional activation for interleukin-2 (Emmel et al 1989, Liu et al 1992, Nelson et al 1993.…”

Section: Introductionmentioning

confidence: 99%

Cyclosporin A improves murine pregnancy outcome in abortion-prone matings: involvement of CD80/86 and CD28/CTLA-4

Zhou¹,

Dong²,

Du³

et al. 2008

Reproduction

View full text Add to dashboard Cite

Immune regulation during pregnancy is complex, and thus an optimal therapy for pregnancy complications is always a big challenge to reproductive medicine. Cyclosporin A (CsA), a potent immunosuppressant, prevents rejection of allografts by hosts, but little is known about the modulating effect of CsA on the materno-fetal relationship. Here, pregnant CBA/J females mated with DBA/2 males as an abortion-prone model were administered with CsA on day 4.5 of gestation, and the pregnant CBA/J females mated with BALB/c males were established as successful pregnancy control. It was demonstrated that administration of CsA at the window of implantation significantly up-regulated the expression of CTLA-4, while down-regulating the levels of CD80, CD86, and CD28 at the materno-fetal interface in the CBA/J!DBA/2 abortion-prone matings, and the embryo resorption rate of the abortion-prone matings reduced significantly after CsA treatment, implying that modulation of costimulatory molecule expression by CsA might contribute to preventing the fetus from maternal immune attack. In addition, treatment with CsA induced enhanced growth and reduced cell apoptosis of the murine trophoblast cells. Together, these findings indicate that CsA has a beneficial effect on the materno-fetal interface in abortion-prone matings, leading to a pregnancy outcome improvement, which might provide new therapeutics for spontaneous pregnancy wastage. Reproduction (2008) 135 385-395

show abstract

Section: Introductionmentioning

confidence: 99%

Cyclosporin A improves murine pregnancy outcome in abortion-prone matings: involvement of CD80/86 and CD28/CTLA-4

Zhou¹,

Dong²,

Du³

et al. 2008

Reproduction

View full text Add to dashboard Cite

show abstract

“…4 This was a transplant world example of how bioequivalence between two agents in a group of normals did not necessarily mean bioequivalence in all groups. An early generic substitute for cyclosporine A modifi ed was approved by the FDA for marketing and sales based on the bioequivalence of a capsule form on the 15 grounds of fulfi llment of the 80-125 rule, but when this particular generic was tested mixed in orange juice, which had been the original standard by which bioequivalent studies were conducted for the branded version of cyclosporine A modifi ed, the data demonstrated that the generic did not fulfi ll the 80-125 rule. This particular generic alternative was removed from the market.…”

Section: Does Bioequivalence In Normalmentioning

confidence: 99%

Generic substitution for immunosuppressive drugs

Helderman

2011

Dialysis & Transplantation

View full text Add to dashboard Cite

The advent of generic alternatives for transplant immunosuppressant drugs has engendered concern and discussion. The process by which the food and drug administration (FDA) approves generic substitutes is reviewed. A category of medicines deﬁned as narrow therapeutic index (NTI) drugs is deﬁned with evidence that many (but not all) of the commonly used transplant medications fall into this category. It is demonstrated that the current FDA standards are inadequate to vet NTI agents. Outcomes data are presented that show generic switching for NTI drugs can be successfully accomplished with careful blood level monitoring, but clinical and ﬁnancial negative consequences can ﬂow from unregulated switching. Recommendations are made for provider use of generic immunsuppressants, for recipient education and response to switching, and for pharmacy shandling of generic alternatives.

show abstract

“…1). Although cyclosporine A is an effective and widely used immunosuppressive drug, numerous adverse effects are associated with therapy [1]. This led to the development of voclosporin, which exhibits greater potency than cyclosporine A in vitro [2,3], as well as in in vivo animal models of transplantation [2,4] and autoimmunity [5] (arthritis).…”

Section: Introductionmentioning

confidence: 99%